ACADIA PHARMACEUTICALS INC (ACAD) Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD Healthcare · Biotechnology
Mkt Cap $3.55B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Acadia Pharmaceuticals will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on November 17, 2026 at 12:40 p.m. GMT.
A live webcast will be available on the company's website under the investors section, with an archived recording available for about one month.
The release contains no financial or pipeline updates beyond conference logistics.
• 4d ago AI analysis › Press Release
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Acadia Pharmaceuticals will report third quarter 2026 financial results on November 4, 2026, after the U.S. market close.
Management will host a conference call and webcast the same day at 4:30 p.m. Eastern Time, with an archive available for approximately 90 days.
This is a scheduling announcement only and contains no financial results or guidance.
• 11d ago AI analysis › Press Release ⚠ 2
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
This is a paid FN Media promotional article surveying the CNS/brain cancer therapeutics space; ACAD is not the subject and made no new disclosure in it.
The only ACAD content is a recap of a previously announced USPTO Notice of Allowance for a patent covering weight-banded dosing of trofinetide in Rett syndrome, expected to extend U.S. protection through March 28, 2041.
The piece is primarily a promotional vehicle for NeOnc Technologies (NTHI), which paid $2,500 for the coverage, plus brief recaps of NBIX, AVXL, and MRK news. Treat as low-signal sector marketing, not issuer news.
• 11d ago AI analysis › Press Release ⚠ 1
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Acadia Pharmaceuticals received a Notice of Allowance from the USPTO for a U.S. patent covering weight-banded dosing of trofinetide in Rett syndrome.
Once issued and including six months of pediatric exclusivity, the patent is expected to extend U.S. protection for trofinetide from July 2036 to March 28, 2041 — nearly five additional years.
Trofinetide is marketed as DAYBUE and DAYBUE STIX, Acadia's key commercial franchise; the extension materially lengthens its exclusivity runway, though the patent still must complete standard issuance steps.
• 1mo ago AI analysis › Press Release ● Major ⚠ 3
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Acadia Pharmaceuticals announced Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis.
The 60 mg once-daily dose narrowly missed the primary SAPS-H+D endpoint (p=0.0603, effect size 0.26) but achieved nominal significance on the key secondary CGI-S-ADP endpoint (p=0.0077, effect size 0.37), with a placebo-like safety profile and no QT or cognition/motor signal.
Acadia will continue its two ongoing Phase 3 studies while amending the program to drop the 30 mg arm, which showed minimal improvement; detailed data will be presented at the CTAD conference November 16-19 in Boston.
The readout is genuinely mixed: pipeline continuity is intact and no approved ADP therapy exists, but the primary-endpoint miss raises execution and regulatory risk for a commercial-stage company leaning on its next wave of products.
• 1mo ago AI analysis › Press Release ● Major
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
The European Commission granted marketing authorization for DAYBU (trofinetide) for Rett syndrome in adults and pediatric patients aged five and older.
This decision makes DAYBU the first and only treatment approved for the disorder in the European Union, covering all 27 member states as well as Iceland, Liechtenstein, and Norway.
Authorization was supported by the Phase 3 LAVENDER study, and Acadia will now initiate pricing and reimbursement negotiations with national authorities.
• 2mo ago AI analysis › Press Release ● Major
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Acadia reported Q2 revenue of $308 million, up 17% year-over-year on an adjusted basis, with diluted EPS rising to $0.18 from $0.16 a year ago.
DAYBUE sales surged 30% to $125 million, while NUPLAZID sales increased 10% to $183 million, prompting the company to raise its full-year 2026 revenue guidance to a range of $1.24 billion to $1.30 billion.
Management also highlighted that Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis are expected between September and October 2026.
• 2mo ago AI analysis › Press Release
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
Acadia Pharmaceuticals announced that it will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026.
The session is scheduled to begin at 1:30 p.m. Eastern Time and will be accessible via live webcast on the company's website.
An archived recording of the presentation will be available on the Acadia website for approximately one month following the event.
• 3mo ago AI analysis › Press Release ● Major
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Acadia Pharmaceuticals received FDA Fast Track designation for Remlifanserin (ACP-204) for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.
The designation is intended to expedite the review of drugs for serious conditions with unmet medical needs, as there are currently no FDA-approved therapies for ADP.
Enrollment in the RADIANT Phase 2 study has been completed with topline results expected between September and October 2026, while screening and enrollment are now underway for the Phase 3 studies.
• 3mo ago AI analysis › Press Release
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Acadia Pharmaceuticals announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, following the close of U.S. financial markets.
Management is scheduled to host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to review the quarterly performance.
Access to the call will be available via the investors section of the company website, with an archive available for approximately 90 days.
• 3mo ago AI analysis › Press Release
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Acadia Pharmaceuticals appointed Carl Segerstrom as Chief People Officer, effective July 6, to lead the company’s global people and culture strategy.
Segerstrom brings over 25 years of experience, most recently serving as Senior Vice President of Human Resources at Merck’s Human Health Division.
He will report to CEO Catherine Owen Adams and join the executive leadership team to support the company's next phase of growth in neurological and rare diseases.
• 3mo ago AI analysis › Press Release
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia reported Q1 total revenue of $268 million, up 10% year-over-year, driven by 20% growth in DAYBUE sales to $101 million and 6% growth in NUPLAZID sales to $167 million.
The company reaffirmed its full-year 2026 financial guidance, including total revenue of $1.22 to $1.28 billion, and remains on track for Phase 2 topline data for remlifanserin in Alzheimer's disease psychosis between August and October.
Management highlighted strong early uptake for the new DAYBUE STIX formulation and maintained confidence in its commercial execution and pipeline development.
• 5mo ago AI analysis › Press Release ⚠ 2
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals announced the planned year-end retirement of Dr. Elizabeth H.Z. Thompson, Head of Research and Development, who will remain in her role until a successor is found.
To ensure continuity during the Phase 2 readout of remlifanserin in Alzheimer’s disease psychosis, Acadia will retain Dr. Thompson as a consultant through at least the end of 2026.
The company has initiated a search for a new R&D leader while confirming that ongoing clinical trials for ADP and Lewy Body Dementia Psychosis remain blinded and are proceeding as planned.
• 6mo ago AI analysis › Press Release
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.
businesswire.com • 6mo ago Press Release
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals announced it will participate in the BofA Securities 2026 Health Care Conference and the 2026 RBC Capital Markets Global Healthcare Conference.
The BofA event features a fireside chat on May 12 in Las Vegas, while the RBC conference chat takes place on May 19 in New York.
Live webcasts will be available on Acadia’s website, with archives accessible for approximately one month.
• 6mo ago AI analysis › Press Release
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
businesswire.com • 6mo ago Press Release ● Major
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
businesswire.com • 6mo ago Press Release
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
businesswire.com • 6mo ago 
